SAB Biotherapeutics (SABS) Current Leases (2020 - 2026)
SAB Biotherapeutics (SABS) reported Current Leases of $763705.0 for Q1 2026, down 3.74% on a YoY basis from $793360.0 in Q1 2025, and down 4.23% quarter-over-quarter from $797402.0 in Q4 2025.
SAB Biotherapeutics (SABS) Current Leases (2020 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Current Leases for 7 years, with the latest figure at $763705.0 in Q1 2026.
- For the quarter ending Q1 2026, Current Leases fell 3.74% year-over-year to $763705.0; the trailing twelve-month figure through Mar 2026 stood at $763705.0 (down 3.74% YoY), and the FY2025 full-year result was $797402.0, up 459.33% from the prior year.
- Current Leases for Q1 2026 stood at $763705.0, down from $797402.0 in the prior quarter.
- The five-year high for Current Leases was $1.2 million in Q2 2022, with the low at $127022.0 in Q2 2023.
- Historically, Current Leases has averaged $433665.1 across 5 years, with a median of $384892.0 in 2024.
- Annual changes were most pronounced in 2023 — Current Leases slumped 89.14% — and 2025, when it soared 494.15%.
- SAB Biotherapeutics' Current Leases stood at $490794.0 in 2022, then sank by 73.1% to $132004.0 in 2023, then advanced by 8.0% to $142563.0 in 2024, then soared by 459.33% to $797402.0 in 2025, then fell by 4.23% to $763705.0 in 2026.
- The last three Current Leases figures came in at $763705.0 (Q1 2026), $797402.0 (Q4 2025), and $151033.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | 763,705.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 763,705.00 |
| Dec 31, 2025 | 797,402.00 |
| Sep 30, 2025 | 151,033.00 |
| Jun 30, 2025 | 815,064.00 |
| Mar 31, 2025 | 793,360.00 |
| Dec 31, 2024 | 142,563.00 |
| Sep 30, 2024 | 384,892.00 |
| Jun 30, 2024 | 137,182.00 |
| Mar 31, 2024 | 134,568.00 |
| Dec 31, 2023 | 132,004.00 |
| Sep 30, 2023 | 528,778.00 |
| Jun 30, 2023 | 127,022.00 |
| Mar 31, 2023 | 518,012.00 |
| Dec 31, 2022 | 490,794.00 |
| Sep 30, 2022 | 140,891.00 |
| Jun 30, 2022 | 1.17 Mn |
| Mar 31, 2022 | 145,898.00 |
| Dec 31, 2021 | 1.14 Mn |
| Dec 31, 2020 | 924,265.00 |